10x Genomics (TXG)
(Delayed Data from NSDQ)
$14.86 USD
-0.88 (-5.59%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $14.90 +0.04 (0.27%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.86 USD
-0.88 (-5.59%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $14.90 +0.04 (0.27%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
Company News for Oct 11, 2024
by Zacks Equity Research
Companies in The News Are: DAL,DPZ,NEOG,TXG
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 31.91% and 1.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 128.57% and 4.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 33.70% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GE HealthCare Technologies (GEHC) Tops Q2 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 2.04% and 1.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Does 10x Genomics (TXG) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
International Markets and 10x Genomics (TXG): A Deep Dive for Investors
by Zacks Equity Research
Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
10x Genomics (TXG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
by Zacks Equity Research
10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 260% and 2.41%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.